CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

Shares of Intellia Therapeutics fell after the company reported a grade 4 adverse event in a study of nex-z, its treatment for hereditary ATTR amyloidosis with polyneuropathy. The stock was down 24% ...

Prothena Corporation’s Phase III AFFIRM-AL trial of birtamimab in individuals with AL amyloidosis misses its primary endpoint ...

Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce ...

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in ...

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study ...

Oppenheimer downgraded Prothena Corporation plc (NASDAQ:PRTA) to Perform from Outperform on May 27 without a price target.

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.